Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 13/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077784 | 0.98 | CASP1 (0.36) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL27766572 | 0.98 | CASP1 (0.36) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL87407 | 0.98 | CASP1 (0.36) | CASP1CYP3A4TDP1RECQLTSHR | |
| Sulfuric Acid SCHEMBL9815941 | 0.96 | CASP1 (0.35) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL2937128 | 0.96 | CASP1 (0.35) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL6418321 | 0.96 | CASP1 (0.35) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL5457190 | 0.96 | CASP1 (0.35) | CASP1CYP3A4TDP1RECQLTSHR | |
| Ethylene SCHEMBL5962491 | 0.96 | CASP1 (0.35) | CASP1CYP3A4TDP1RECQLTSHR | |
| SCHEMBL28432001 | 0.90 | CASP1 (0.33) | CASP1CYP3A4 | |
| Monoethanolamine SCHEMBL10816531 | 0.88 | CASP1 (0.32) | CASP1MAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1220886-B1 | LIQUID CLEANSING COMPOSITION COMPRISING LAMELLAR PHASE HAVING LOW SALT LEVEL | UNILEVER PLC (GB) | 2014-03-05 | — | — | EP | claimed |
| EP-1607471-B2 | Extrudable multiphase composition comprising lamellar phase inducing structurant in each phase | UNILEVER PLC (GB) | 2013-08-21 | — | — | EP | claimed |
| EP-1607471-B1 | Extrudable multiphase composition comprising lamellar phase inducing structurant in each phase | UNILEVER PLC (GB) | 2009-11-25 | — | — | EP | claimed |
| EP-1607471-A1 | Extrudable multiphase composition comprising lamellar phase inducing structurant in each phase | UNILEVER PLC (GB) | 2005-12-21 | — | — | EP | claimed |
| EP-1267825-B1 | EXTRUDABLE MULTIPHASE COMPOSITION COMPRISING A LAMELLAR PHASE AND AN ISOTROPIC PHASE | UNILEVER PLC (GB) | 2005-11-02 | — | — | EP | claimed |
| US-6534456-B2 | Cleaning compounds; storage stability | UNILEVER HOME AND PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-03-18 | — | — | US | claimed |
| US-6534457-B2 | Cleaning compounds; storage stability | UNILEVER HOME AND PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-03-18 | — | — | US | claimed |
| US-6426326-B1 | SURFACTANT MIXTURE | UNILEVER HOME & PERSON CARE USA, A DIVISION OF CONOPCO, INC. | 2002-07-30 | — | — | US | claimed |
| EP-1220886-A1 | LIQUID CLEANSING COMPOSITION COMPRISING LAMELLAR PHASE HAVING LOW SALT LEVEL | UNILEVER PLC (GB) | 2002-07-10 | — | — | EP | claimed |
| US-20020010111-A1 | Extrudable multiphase composition comprising lamellar phase inducing structurant in each phase | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | claimed |
| US-20020010110-A1 | Extrudable multiphase composition comprising a lamellar phase and an isotropic phase | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001019949-A1 | LIQUID CLEANSING COMPOSITION COMPRISING LAMELLAR PHASE HAVING LOW SALT LEVEL | UNILEVER PLC (GB) | 2001-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010111-A1 | Extrudable multiphase composition comprising lamellar phase inducing structurant in each phase | ABHD6, AQP1, LIPA | CASP1 3147/4885CYP3A4 4564/4885TDP1 1192/4885 |
| US-20020010110-A1 | Extrudable multiphase composition comprising a lamellar phase and an isotropic phase | PIK3C2A, ABHD6, PIK3C2G | CASP1 4050/4885CYP3A4 4714/4885TDP1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.